Fig. 3. KVX-053 reduces S1SP-inuced alveolar “cytokine
storm” in BALF 72 h after S1SP instillation. Means ± SEM; n = 6-10
mice/group; *P < 0.05; **P < 0.01, ***P <
0.001 with one-way ANOVA followed by Tukey’s test. BALF, bronchoalveolar
lavage fluid; SARS-CoV-2, severe acute respiratory syndrome
coronavirus-2; S1SP, subunit 1 of spike protein.
Fig. 4. Histological evaluation of therapeutic properties
of KVX-053 against S1SP-induced acute lung injury. H&E staining of
lung sections demonstrates septal thickening, neutrophil infiltration,
and edema in S1SP-instilled mice and a mild leukocyte infiltration in
S1SP-instilled mice, treated with KVX-053 (10 mg/kg i.p./day) (A). The
Lung Injury Score quantifies severe lung injury in S1SP-instilled mice
compared to control mice, and milder pathology in S1SP-instilled and
treated with KVX-053.Black scale bar = 50 μm,
white scale bar = 10 μm. Means ± SEM; n = 6 mice/group; ***P <
0.001 with one-way ANOVA followed by Tukey’s test.